Back to top
more

DURECT (DRRX)

(Delayed Data from NSDQ)

$1.34 USD

1.34
21,095

-0.01 (-0.74%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $1.34 0.00 (0.00%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -16.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -15.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -33.33% and -66.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -23.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Forget Bargain Hunting: Play 5 Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Durect (DRRX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Durect (DRRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Durect (DRRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 75.00% and 30.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER

by Zacks Equity Research

Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.